Bactorinol® Nasal Spray With Reduced-Dose Mometasone in Adults With Chronic Rhinosinusitis
Condition(s) studied
Investigational drug(s) / intervention(s)
Bactorinol® (manufacturer: PharmExtracta S.p.A.): Bactorinol® nasal spray, 3 puffs per nostril twice daily for 12 weeks.
Mometasone Furoate Nasal Spray: Mometasone furoate nasal spray administered for 12 weeks. The Treated Group receives 1 puff daily and the Control Group receives 2 puffs daily.
Study summary
Chronic rhinosinusitis (CRS) is a persistent inflammatory disease of the nose and sinuses, defined by the presence of symptoms for at least 12 weeks. Medical treatment of CRS is mainly based on topical therapies aimed at controlling mucosal inflammation and improving naso-sinus clearance. However, despite these treatments, some patients continue to experience persistent or recurrent symptoms.
This prospective, single-center, randomized, controlled, non-profit study aims to evaluate the clinical efficacy of Bactorinol® nasal spray in patients with chronic rhinosinusitis, in order to reduce the impact of CRS symptoms on patients' quality of life in a non-inferior manner compared with treatment with the full dose of mometasone furoate nasal spray.
Participants will be randomly assigned in a 1:1 ratio to receive mometasone furoate nasal spray 1 puff daily plus Bactorinol® nasal spray 3 puffs per nostril twice daily, or mometasone furoate nasal spray 2 puffs daily. The treatment period will last 12 weeks.
Eligibility
Primary outcome measure(s)
- Change in Quality of Life Assessed by the Sino-Nasal Outcome Test-22 (SNOT-22) — Baseline to Week 12
Change in the impact of chronic rhinosinusitis symptoms on patients' quality of life will be assessed using the validated Sino-Nasal Outcome Test-22 (SNOT-22) scale in both study groups.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Armonia Centro Polispecialistico | Porto Mantovano | Lombardy |
More Liaquat University of Medical & Health Sciences trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07800273 on ClinicalTrials.gov ↗ ← All trials in Italy